Recent Company News

• 08:03 AM ET Jun 16, 2026
  

  Innoviva Specialty Therapeutics announces distribution and licensing agreement with Dr. Reddy's for XACDURO in select international markets ($22.42, 0.00)

• 04:24 AM ET Jun 13, 2026
  

  Dr. Reddy's announces first-to-market launch of Bosutinib Tablets 400mg in US (INR 1273.90, 0.00)

• 08:56 AM ET May 29, 2026
  

  NYSE Content Update: Dell Technologies Reports 88% Revenue Increase YoY

• 07:28 PM ET May 27, 2026
  

  Immutep to present data from 5 clinical trials of efti in combination with standard-of care therapies in late-stage cancer patients at ASCO, suggests efti induced broad immune activation (A$0.05, 0.00)

• 06:28 AM ET May 26, 2026
  

  Shanghai Junshi Biosciences meets primary endpoint in phase III clinical trial of Toripalimab for treatment of non-small cell lung cancer (HK$21.66, 0.00)

• 05:52 AM ET May 21, 2026
  

  NMPA approves marketing of Junshi Biosciences's JS001 to be combined with disitamab vedotin for urothelial carcinoma with HER2 expression (HK$23.86, 0.00)

• 04:13 AM ET May 13, 2026
  

  Dr. Reddy's Laboratories upgraded to accumulate from reduce at Prabhudas Lilladher (INR 1271.65, +1.55)

• 04:03 AM ET May 13, 2026
  

  Dr. Reddy's Laboratories downgraded to accumulate from buy at Elara Capital (INR 1266.60, -3.50)